We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The current PRME market cap is 435.45M. The company's latest EPS is USD -1.5106 and P/E is -2.21.
Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | ||
Total Revenue | 0 | 0 | 0 | 591k | 0 |
Operating Income | -45.26M | -51.46M | -68.04M | -48.34M | -55.67M |
Net Income | -42.39M | -50.71M | -65.64M | -45.76M | -55.33M |
Year End 31 December 2023 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 5.21M | 0 | 0 | 0 |
Operating Income | -932k | -84.47M | -116.54M | -204.79M |
Net Income | -5.06M | -184.12M | -142.01M | -198.13M |
Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | ||
Total Assets | 280.87M | 239.15M | 193.85M | 311.38M | 259.71M |
Total Liabilities | 40.76M | 45.19M | 60.78M | 67.62M | 63.12M |
Total Equity | 240.1M | 193.96M | 133.07M | 243.77M | 196.59M |
Year End 31 December 2023 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 54.78M | 301.86M | 360.31M | 193.85M |
Total Liabilities | 21.31M | 62.3M | 44.04M | 60.78M |
Total Equity | 2.34M | -156.24M | 316.27M | 133.07M |
Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | ||
Operating | -82.38M | -121.55M | -165.41M | -67.71M | -113.2M |
Investing | 15.2M | -22.57M | 18.71M | -37.03M | -30.14M |
Financing | 143k | 461k | 655k | 157.33M | 157.36M |
Year End 31 December 2023 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | -5.54M | -34.08M | -131.83M | -165.41M |
Investing | -1.06M | -73.63M | -47.1M | 18.71M |
Financing | 34.93M | 269.28M | 181.49M | 655k |
Market Cap | 435.45M |
Price to Earnings Ratio | -2.21 |
Price to Sales Ratio | 0 |
Price to Cash Ratio | 10.54 |
Price to Book Ratio | 3.29 |
Dividend Yield | - |
Shares Outstanding | 131.16M |
Average Volume (1 week) | 1.31M |
Average Volume (1 Month) | 1.16M |
52 Week Change | -53.70% |
52 Week High | 9.86 |
52 Week Low | 2.85 |
Spread (Intraday) | 0.03 (0.9%) |
Company Name | Prime Medicine Inc |
Address |
corporation trust center wilmington, delaware 19801 |
Website | https://www.primemedicine.com |
Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions